Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong ...

Aurobindo Pharma’s (ARBP) Q2FY25 EBITDA of Rs15.6bn (down 3% QoQ) with OPM of 20.1%, was 9% below our estimate. The miss was largely because of higher PenG related operational cost and shipping ...

Quarterly revenue reached Rs. 7,796 crore, up 8% y-o-y and 3% q-o-q, exceeding our estimates by 1%, while PAT was Rs. 817 crore, showing a 9% y-o-y increase but an 11% q-o-q decrease, falling 19% ...

Aurobindo Pharma subsidiary CuraTeQ Biologics has received a GMP certificate of compliance for its biosimilars manufacturing facility from the European Medicines Agency (EMA). The GMP inspection ...

Aurobindo Pharma consolidated net profit for the September quarter increased 8.6% to ₹816.9 crore compared to ₹751.9 crore year earlier. On a sequential basis the net profit was 11% lower ...

Hyderabad-based Aurobindo Pharma has registered a growth of 8.6 per cent in net profit for the quarter ended September 30, 2024 at Rs. 816.95 crore as compared to Rs. 751.94 crore during the same ...

Aurobindo Pharma's Hyderabad-based biosimilars facility receives GMP certification from the European Medicines Agency, paving the way for approvals for three biosimilars. New Delhi, Nov 12 (PTI) ...

Aurobindo Pharma witnessed an 8.6% YoY increase in net profit, reaching Rs 817 crore in Q2 FY25, driven by robust sales in Europe and growth markets. Despite a dip in US formulations revenue, the ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a GMP certificate from the European Medicines Agency for its biosimilars manufacturing facility in Hyderabad. This certification from a ...

New Delhi, Nov 12 (PTI) Aurobindo Pharma on Tuesday said its unit has received GMP certificate of compliance for its Hyderabad-based biosimilars manufacturing facility from the European Medicines ...

Aurobindo Pharma Ltd on Wednesday said it will acquire the balance 49 per cent stake in GLS Pharma Ltd for Rs 22.5 crore to make the latter a wholly-owned subsidiary. Intimation of entering into a ...